Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes

被引:26
作者
Manning, PJ [1 ]
Sutherland, WHF [1 ]
Allum, AR [1 ]
de Jong, SA [1 ]
Jones, SD [1 ]
机构
[1] Univ Otago, Sch Med, Dunedin Sch Med, Dept Med & Surg Sci,Sect Med, Dunedin, New Zealand
关键词
diabetes; hormone replacement therapy; C-reactive protein; cell adhesion molecules;
D O I
10.1046/j.1464-5491.2002.00808.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To test the effect of oral hormone replacement therapy (HRT) on plasma C-reactive protein (CRP), soluble vascular cell adhesion molecule-1 (VCAM-1), soluble intercellular adhesion molecule-1 (ICAM-1) and IL-6 concentrations and leucocyte count in post-menopausal women with Type 2 diabetes. Methods Post-menopausal women with Type 2 diabetes (n = 61) were randomized in a double-blind fashion to receive either continuous combined hormone replacement therapy ( n = 29) with conjugated equine oestrogen (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day) or placebo (n = 32) for 6 months. Study variables were measured at baseline and at the end of the study. Results Eight women randomized to hormone replacement therapy and four women assigned to placebo group dropped out of the study. Plasma CRP increased (2.2 mg/l, 95% confidence interval 0.3-4.1 mg/l) significantly (P = 0.02) in women treated with HRT (<n = 21) compared with placebo (n = 29) taking baseline CRP, body mass index (BMI) and smoking status into account. Plasma levels of cell adhesion molecules, IL-6 and leucocyte count did not change significantly during the study. Conclusions These findings indicate that oral HRT with conjugated equine oestrogen plus medroxyprogesterone acetate increases plasma CRP levels but not necessarily global inflammatory activity in post-menopausal diabetic women. An increase in plasma CRP may potentially increase risk of a cardiovascular event.
引用
收藏
页码:847 / 852
页数:6
相关论文
共 32 条
[21]   NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X [J].
Pickup, JC ;
Mattock, MB ;
Chusney, GD ;
Burt, D .
DIABETOLOGIA, 1997, 40 (11) :1286-1292
[22]   Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men [J].
Ridker, PM ;
Hennekens, CH ;
Roitman-Johnson, B ;
Stampfer, MJ ;
Allen, J .
LANCET, 1998, 351 (9096) :88-92
[23]   Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [J].
Ridker, PM ;
Cushman, M ;
Stampfer, MJ ;
Tracy, RP ;
Hennekens, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (14) :973-979
[24]   C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women [J].
Ridker, PM ;
Hennekens, CH ;
Buring, JE ;
Rifai, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (12) :836-843
[25]  
SALOBIR BG, 2000, EXCERPTA MED INT C S, V1215, P283
[26]   Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes [J].
Sattar, N ;
Perera, M ;
Small, M ;
Lumsden, MA .
LANCET, 1999, 354 (9177) :487-488
[27]   Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women [J].
van Baal, WM ;
Kenemans, P ;
van der Mooren, MJ ;
Kessel, H ;
Emeis, JJ ;
Stehouwer, CDA .
THROMBOSIS AND HAEMOSTASIS, 1999, 81 (06) :925-928
[28]  
van Baal WM, 1999, EUR J CLIN INVEST, V29, P913
[29]   The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial [J].
Walsh, BW ;
Paul, S ;
Wild, RA ;
Dean, RA ;
Tracy, RP ;
Cox, DA ;
Anderson, PW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :214-218
[30]  
WARNICK GR, 1982, CLIN CHEM, V28, P1379